NVCN
vs
S
S&P TSX Composite Index (Canada)

Over the past 12 months, NVCN has underperformed S&P TSX Composite Index (Canada), delivering a return of 0% compared to the S&P TSX Composite Index (Canada)'s +21% growth.
Stocks Performance
NVCN vs S&P TSX Composite Index (Canada)
Performance Gap
NVCN vs S&P TSX Composite Index (Canada)
Performance By Year
NVCN vs S&P TSX Composite Index (Canada)
Neovasc Inc
Glance View
Neovasc, Inc. engages in the development, manufacture and marketing of medical devices. The company is headquartered in Richmond British Columbia, British Columbia. The company went IPO on 2001-05-23. The firm develops, manufactures and markets products for the cardiovascular marketplace. The firm's products include the Neovasc ReducerTM (Reducer), for the treatment of refractory angina, a painful and debilitating condition that occurs when the coronary vasculature delivers an inadequate supply of blood to the heart muscle and the TiaraTM (Tiara), for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. Its wholly owned subsidiaries include Neovasc Medical Inc., Neovasc Tiara Inc., Neovasc (US) Inc., Neovasc Medical Ltd., B-Balloon Ltd., Neovasc GmbH, and Neovasc Management Inc.
